18889881171
Kalkine 0
countryflagUS

Swedish Orphan Biovitrum AB (publ)

Healthcare US BIOVF

30.5USD
-(-%)

Last update at 2025-05-12T20:00:00Z

Day Range

27.0027.00
LowHigh

52 Week Range

22.4032.25
LowHigh

Fundamentals

  • Previous Close 30.50
  • Market Cap9977.09M
  • Volume100
  • P/E Ratio30.04
  • Dividend Yield-%
  • EBITDA9454.00M
  • Revenue TTM25435.00M
  • Revenue Per Share TTM73.87
  • Gross Profit TTM 14377.00M
  • Diluted EPS TTM0.93

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 3321.00M 3295.00M 4217.00M 4247.00M 3081.74M
Minority interest - - - - 0.00000M
Net income 2638.00M 2679.00M 3245.00M 3304.00M 2417.80M
Selling general administrative 7847.00M 6294.00M 5981.00M 4935.00M 2510.74M
Selling and marketing expenses - - - 4935.00M 2510.74M
Gross profit 14014.00M 12045.00M 12036.00M 10913.00M 6723.47M
Reconciled depreciation 2419.00M 2006.00M 2023.00M 1589.00M 484.57M
Ebit 3813.00M 3733.00M 4818.00M 4533.00M 3138.20M
Ebitda 6198.00M 5776.00M 6297.00M 6043.00M 3622.77M
Depreciation and amortization 2385.00M 2043.00M 1479.00M 1510.00M 484.57M
Non operating income net other - - - - 0.00000M
Operating income 3813.00M 3733.00M 4818.00M 4533.00M 3121.97M
Other operating expenses 14945.00M 11742.00M 10798.00M 9749.00M 6014.45M
Interest expense 458.00M 419.00M 454.00M 241.00M 56.46M
Tax provision 683.00M 616.00M 972.00M 942.00M 663.94M
Interest income 5.00M 0.00000M 1.00M 5.00M 2.74M
Net interest income -481.00000M -454.00000M -486.00000M -255.00000M -56.91700M
Extraordinary items - - - - 0.00000M
Non recurring - - - - 0.00000M
Other items - - - - 0.00000M
Income tax expense 683.00M 616.00M 972.00M 942.00M 663.94M
Total revenue 18790.00M 15529.00M 15261.00M 14248.00M 9138.89M
Total operating expenses 10169.00M 8258.00M 7573.00M 6414.00M 3599.03M
Cost of revenue 4776.00M 3484.00M 3225.00M 3335.00M 2415.43M
Total other income expense net -492.00000M -438.00000M -601.00000M -286.00000M -40.23300M
Discontinued operations - - - - 0.00000M
Net income from continuing ops 2638.00M 2679.00M 3245.00M 3305.00M 2417.80M
Net income applicable to common shares 2638.00M 2679.00M 3245.00M 3304.00M 2418.00M
Preferred stock and other adjustments - - - - 0.00000M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 74027.00M 52496.00M 48661.00M 48283.00M 45658.00M
Intangible assets 49341.00M 33006.00M 32135.00M 32918.00M 30736.00M
Earning assets - - - - -
Other current assets 7893.00M 123.00M 1.00M 2.00M 1.00M
Total liab 40160.00M 25971.00M 25458.00M 28077.00M 28728.00M
Total stockholder equity 33867.00M 26525.00M 23203.00M 20206.00M 16930.00M
Deferred long term liab - - 517.00M 546.00M 492.00M
Other current liab 9036.00M 7676.00M 1041.00M 711.00M 1562.00M
Common stock 194.00M 170.00M 169.00M 167.00M 165.00M
Capital stock 194.00M 170.00M 169.00M 167.00M 165.00M
Retained earnings 18055.00M 15793.00M 13155.00M 10477.00M 7269.00M
Other liab - 7943.00M 7673.00M 7189.00M 6526.00M
Good will 9642.00M 7007.00M 6288.00M 5873.00M 6678.00M
Other assets - 1.00M 1338.00M 1204.00M 897.00M
Cash 904.00M 1361.00M 1045.00M 404.00M 737.00M
Cash and equivalents - - - - -
Total current liabilities 19095.00M 14857.00M 8761.00M 10443.00M 5741.00M
Current deferred revenue 2904.00M - 5280.00M 5037.00M 3399.00M
Net debt 19581.00M 7739.00M 9861.00M 14167.00M 15823.00M
Short term debt 8961.00M 5929.00M 1882.00M 4126.00M 99.00M
Short long term debt 8813.00M 5795.00M 1768.00M 4015.00M -
Short long term debt total 20485.00M 9100.00M 10906.00M 14571.00M 16560.00M
Other stockholder equity 15618.00M 10562.00M 9879.00M 9562.00M 9496.00M
Property plant equipment - 274.00M 493.00M 534.00M 518.00M
Total current assets 12671.00M 11210.00M 8778.00M 8168.00M 7323.00M
Long term investments - - - - 404.00M
Net tangible assets - -13488.00000M -14704.00000M -18039.00000M -19990.00000M
Short term investments 105.00M - -9.00000M - -
Net receivables 7062.00M 5248.00M 4308.00M 4709.00M 4813.00M
Long term debt 11356.00M 2971.00M 8777.00M 10137.00M 16141.00M
Inventory 3874.00M 3332.00M 3424.00M 3053.00M 1772.00M
Accounts payable 1024.00M 1252.00M 558.00M 569.00M 681.00M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -934.00000M - - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 2085.00M 121.00M 1.00M -1.00000M -2.00000M
Deferred long term asset charges - - - - -
Non current assets total 61356.00M 41285.00M 39883.00M 40115.00M 38335.00M
Capital lease obligations 316.00M 334.00M 361.00M 419.00M 419.00M
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -1477.00000M -367.00000M -120.00000M -120.00000M -120.00000M
Change to liabilities 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total cashflows from investing activities -1477.00000M -367.00000M -3964.00000M -21685.00000M -575.00000M
Net borrowings -2553.00000M -4123.00000M -1570.00000M 15780.00M -2.00000M
Total cash from financing activities -2991.00000M -4474.00000M -1570.00000M 15780.00M -2.05300M
Change to operating activities -807.00000M 980.00M 1069.00M 1221.00M 659.00M
Net income 3321.00M 3295.00M 3245.00M 3304.00M 2417.80M
Change in cash 316.00M 641.00M -333.00000M -2262.00000M 1520.25M
Begin period cash flow 1045.00M 404.00M 737.00M 2999.00M 1478.50M
End period cash flow 1361.00M 1045.00M 404.00M 737.00M 2998.74M
Total cash from operating activities 4665.00M 5470.00M 5214.00M 3634.00M 2090.28M
Issuance of capital stock - - - - -
Depreciation 2419.00M 2006.00M 2023.00M 1589.00M 484.57M
Other cashflows from investing activities - - - -1.00000M -1.00000M
Dividends paid - - - - 0.00000M
Change to inventory 413.00M -318.00000M -1306.00000M -459.00000M -230.84400M
Change to account receivables -1982.00000M 452.00M -185.00000M -2428.00000M -679.00000M
Sale purchase of stock - - - - 0.00000M
Other cashflows from financing activities 13103.00M 13717.00M 13457.00M 15780.00M -575.53700M
Change to netincome 556.00M -322.00000M 99.00M 487.00M -562.00000M
Capital expenditures 1477.00M 370.00M 3852.00M 9746.00M 577.88M
Change receivables - - - - 0.00000M
Cash flows other operating - - - - 0.00000M
Exchange rate changes - - - - 0.00000M
Cash and cash equivalents changes - - - - 0.00000M
Change in working capital -806.00000M 1114.00M -184.00000M -1666.00000M -250.46800M
Stock based compensation - - 114.00M 80.00M 45.69M
Other non cash items -269.00000M -945.00000M -351.00000M -417.00000M -503.91500M
Free cash flow 3188.00M 5100.00M 1362.00M -6112.00000M 1512.40M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
BIOVF
Swedish Orphan Biovitrum AB (publ)		 - -% 30.50 30.04 20.08 0.39 2.83 4.94 13.57
ZTS
Zoetis Inc		 -0.29 0.18% 161.63 40.18 30.96 10.67 17.60 11.27 26.18
MKKGY
Merck KGaA ADR		 0.44 1.57% 28.43 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 5.48 4.01% 142.15 21.73 14.95 3.16 2.15 3.56 12.82
TAK
Takeda Pharmaceutical Co Ltd ADR		 -0.455 3.21% 13.73 32.67 11.53 0.01 0.87 0.02 0.07

Reports Covered

Stock Research & News

View All

Profile

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company also provides other products, such as Akynzeo, Tegsedi, Jyseleca, Kepivance, Aloxi, and Waylivra. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Sanofi, Apellis Pharmaceuticals Inc., ADC Therapeutics SA, and Cartesian Therapeutics, Inc. Swedish Orphan Biovitrum AB (publ) was incorporated in 1939 and is headquartered in Solna, Sweden.

Swedish Orphan Biovitrum AB (publ)

TomtebodavAegen 23A, Solna, Sweden, 112 76

Key Executives

Name Title Year Born
Dr. Guido Oelkers CEO & Pres 1965
Dr. Anders Ullman M.D., Ph.D. Head of R&D & Medical Affairs and Chief Medical Officer 1956
Mr. Henrik Stenqvist Chief Financial Officer 1968
Ms. Christine Wesstrom Head of Technical Operations 1975
Mr. Thomas Kudsk Larsen Head of Communication & Investor Relations 1974
Mr. Torbjörn Hallberg Gen. Counsel and Head of Legal Affairs & HR 1969
Mr. Daniel Rankin Head of Strategy & Corp. Devel. 1980
Pablo de Mora Head of Global Marketing & Access 1968
Mr. Philip Wood Head of Haematology 1968
Ms. Konstantina Karampela Sr. Director of European Commercial Operations (Specialty Care and Partner Products) NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.